Oval Cell Marker Antibody (OC2-4E8) [Janelia Fluor® 669]

Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.

Facultative liver stem cell activation was originally described in the rat, where chemical damage and partial hepatectomy caused the emergence of a new cell type, the oval cell. These cells are thought to be bipotential progenitors capable of yielding both hepatocytes and bile ducts (1). To properly determine the molecular regulation of the progenitor process, appropriate markers are needed to identify and isolate cells that emerge during the oval cell response.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Array NBP1-18971JF669

• Oval Cell Marker Antibodies